SCHEMBL5778875

SCHEMBL5778875

CCOC(=O)c1cnc(Cl)cc1-c1ccccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 2/20 0.53
MAPT P10636 7/20 0.48
HPGD P15428 2/20 0.48
TSHR P16473 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
GABRP O00591 2/20 0.46
GABRD O14764 2/20 0.46
GABRA1 P14867 2/20 0.46
GABRB1 P18505 2/20 0.46
GABRG2 P18507 2/20 0.46
GABRB3 P28472 2/20 0.46
GABRA5 P31644 2/20 0.46
GABRA3 P34903 2/20 0.46
GABRA2 P47869 2/20 0.46
GABRB2 P47870 2/20 0.46
GABRA4 P48169 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30898516 0.86 KDM4E (0.50) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL22717380 0.86 KDM4E (0.50) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL5091522 0.85 SMN1; SMN2 (0.56) ALDH1A1KDM4EMAPTHPGDTSHR
SCHEMBL20806339 0.84 TSHR (0.58) ALDH1A1KDM4EMAPTHPGDTSHR
SCHEMBL22717493 0.82 ALDH1A1 (0.47) ALDH1A1KDM4EMAPTTSHRMEN1
SCHEMBL29574145 0.82 ALDH1A1 (0.47) ALDH1A1KDM4EMAPTTSHRMEN1
SCHEMBL15051043 0.81 MAPT (0.45) ALDH1A1KDM4EMAPTHPGDTSHR
SCHEMBL28109263 0.80 CDC7 (0.52) ALDH1A1KDM4EMAPTHPGDTSHR
SCHEMBL31167806 0.80 DPP4 (0.50)
SCHEMBL190973 0.80 BAZ2B (0.51) ALDH1A1KDM4EMAPTHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309559-B1 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2006-06-07 EP disclosed
US-6770637-B2 N-(3,5-BIS-TRIFLUOROMETHYL-BENZYL)-6-(4-HYDROXYACETYL-PIPERAZIN-1 -YL)-N-METHYL-4-O-TOLYL-NICOTINAMIDE, FOR EXAMPLE HOFFMANN-LA ROCHE INC. 2004-08-03 US disclosed
EP-1309559-A1 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-14 EP disclosed
US-20020040040-A1 Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors F. HOFFMAN-LA ROCHE AG (CH) 2002-04-04 US disclosed
WO-2002016324-A1 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040040-A1 Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors NPSR1, NTSR1, NTSR2 ALDH1A1 2396/4885KDM4E 2842/4885MAPT 3805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.